APOLLO-B Phase 3 Study Results Presented during AHA Scientific Sessions 2023

13 Nov, 2023 APOLLO-B Phase 3 Study Results Presented during AHA Scientific Sessions 2023

24-month results, including data on the odds of disease progression as assessed by NYHA class and disease stage, from an interim analysis of the open-label extension period of the APOLLO-B Phase 3 study of investigational patisiran in patients with the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis were presented during the American Heart Association (AHA) Scientific Sessions 2023.

Hung, et al. “APOLLO-B, a Study of Patisiran in Patients with Transthyretin Cardiac Amyloidosis: Primary Long-term Results from the Open-Label Extension Period”